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ABSTRACT  
Personalized medicine is a model for health care which is a combination of preventive, personalized, participatory and 
predictive measures. It is an approach for better treatment by identifying the disease causing genomic makeup of an 
individual. Personalized medicine is a broad field and it can be used for the diagnosis of various diseases like cancers, 
Alzheimer, Hepatitis, Cardiac diseases etc. It is an emerging field with lots of hope in the future. This review is basically 
based on characteristics of personalized medicine and its implementation in various diseases like lung cancer, renal 
cancer and rheumatoid arthritis. Further, the initiation taken by the European Union towards the development of 
personalized medicine and the challenges faced during the data collection, development of medicine and clinical trials 
were also discussed. The personalized medicine coalitions (PMC) have approved various novel medicines as 
personalized medicine under US FDA. 
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INTRODUCTION 
Personalized medicine is a unique approach refers to a 
tailoring of medical treatment for the individual 
characteristics of patients. Personalized medicine is also 
known for precision medicine. These medicines are made 
based upon the genetic setup of human genome. It 
becomes the primary concern for the diagnosis, 
prevention and treatment of any disease and personalized 
medicine is based on the pharmacogenomics and 
genomics1. The advancement of molecular profile 
technology to get access on RNA, DNA and protein will 
potentiate the personalized medicine for managing the 
disease. Precision medicine having various advantages 
over conventional medicine like optimum therapy 
required, increase safety and efficacy, decrease adverse 
drug reaction, enhance patient compliance, reduce cost, 
time and clinical trials failure rate. Personalized medicine 
is a type of targeted treatment and it is helpful for wide 
spectrum of diseases like lung cancer, brain tumor, 
prostate cancer, rheumatoid arthritis, autoimmune 
diseases etc. This technology is also called for next 
generation sequencing (NGS). It is an evolving field 
where physicians use some diagnostic test for treating the 
patient and after combining both tests and medical history 
of patients, they can easily develop targeted medicine for 
individual patient2. 
 
PERSONALISED MEDICINE FOR LUNG CANCER 
The systemic treatment for lung cancer is very limited, 
the targeted disease treatment is common now days and 
many more drugs and synthesis as well as approved like 
monoclonal antibody (mAbs) and tyrosine kinase 
inhibitors (TKIs). These are active against epidermal 
growth factor receptor (EGRF) and got response more 
than 70%3. According to further studies, it was observed 
that targeted drugs worsen the condition more than the 
cytotoxic drugs and these drugs are more costly than 
conventional drugs4. Non-small cell lung cancer 
(NSCLS) causes more number of cancers and these cells 
are having the characteristics of uncontrolled cell growth. 
An approach towards personalized medicine for cancer 
management is positron emission tomography (PET) and 
radioactive labeled drugs. Concentration of metabolite 
and pharmacokinetics was determined by regular 
assessment of blood sample urine etc5. 
The PET is a type of imaging technique used as a 
personalized medicine by utilizing gamma rays which 
produces 3 dimensional (3D) images6. The PET is having 
an advantage of targeting the diseased site by using radio 
labeled drugs which will further help in developing 
targeted drugs for the treatment as a personalized 
medicine. The pharmacokinetics (PK) of targeted drugs 
were studied and new medicine can be made and also 
binding of radio labeled drug with tumor can also 
predicted.  Immuno-PET is a type imaging system that is 
mostly used as an antigen therapy. The MAbs had been 
investigated as an agent in Immuno-PET and mAbs are 
labeled with radionucleoids for example 89Zr 7. Because 
of slow PK, dynamic scanning was not possible in case of 
radio labeled mAbs. Static image utilizes the tumor-to-
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blood, standardized uptake value (SUV) and tumor-to-
reference tissue ratios. After the binding of mAbs, target 
cell internalize the mAbs. Some radionucleoids get 
degraded and washed out from the cell such as 124I, 76Br 
etc8. 
The TKI-PET is also a tool for imaging damaged cells 
and it mostly targets the EGFR. TKI are tiny molecules 
having the rapid pharmacokinetic profiling which inhibits 
the activity of kinase proliferating path. For binding with 
target tyrosine kinase, TKI competes with ATP for 
example, EGFR kinase domain was targeted by erlotinib 
after competing with adenosine triphosphate (ATP) [9]. 
Typically; TKIs are labeled with 18F or 11C because of 
their short half-life activity they get better fit with 
biological half-life. After injecting the radio labeled 
TKIs, they get rapidly bind with the target cells and it 
frequently undergoes biliary and renal clearance. In this 
case, dynamic scanning is mostly used for assessment of 
PK modeling and uptake of quantitative tracing. There is 
an advantage of utilizing short live nucleotides is that it is 
easily decade and patient can take this therapy second 
time just after the first time10. The marketed personalized 
medicines are represented in Table 1.  
 
PERSONALISED MEDICINE FOR RENAL 
CARCINOMA 
It is the most common problem facing by whole world 
especially Europe and deadliest problem there are two 
types of renal carcinoma one is renal pelvis carcinoma 
and other is renal cell carcinoma. 1000’s of people are 
diagnosed with malignant tumor every year and the most 
common is nephroblastoma also called for Wilm’s tumor 
(WT). The common symptoms are abdomen pain and 
swelling and it is mostly occur in children. Children 
oncology group (COG) identified the biomarker that is 
responsible for nephroblastoma. Doxorubicin (DOX) with 
Vincristine (VCR) and Actinomycin-D (ACT-D) was 
given to the stage I, and II patients but there was no 
significant effect [12]. 
In preclinical testing authors observed that after targeting 
the Insulin growth factor (IGF) pathway by IMC-A12 
(monoclonal antibody), there was arrest in cell cycle as 
well as reduction in size of tumor. It depicted the good 
antitumor activity and can be effective for 
rhabdomysarcoma patient also13. Weiqel et al, aimed their 
study to know the effectiveness of cixutumumab. The 
drug (9 mg/kg) through intravenous route was 
administered to the patients and it was observed that 
children tolerated cixutumumab easily and better agent 
for IGF inhibition14.  
For early detection of tumor a combine therapy (drug and 
antibody) was employed by Wood et al. An example of 
this combination system is lorvotuzumab mertansine, 
conjugation of cytotoxic and mAbs to CD-56 which 
shows good antitumor activity against WT xenografts15. 
There is 50-70% subjects suffering from clear cell renal 
cell carcinoma (ccRCC), the pathophysiology of 
treatment is to target the Von hipple lindau (VHL) and 
inactivation of components present in signaling pathway. 
The VHL is a biomarker that is responsible for renal 
carcinoma and other markers are carbonic anhydrase and 
VEGF. The recently developed personalized medicines 
are bevacizumab for bevicizumab, axitinib, sorafinib, and 
temsirolimus16. Now some people became resistant to 
these medicines and sunitinib is the commonly used first 
line drug for treatment. So, for overcoming to this 
problem and also for enhancing the efficacy of RCC 
therapy drugs should be combined with antiangiogenic 
agent. Xu et al, patient get treated by pazopanib and they 
observed that there is an association between Single 
nucleotide polymorphism (SNP) and progression free 
survival and higher response as compared to earlier 
treatment17. 
Renal cell carcinoma (RCC) initiatives 
Cancer genomic of the kidney consortium (CAGEKID) 
consisting 14 members from the 6 different countries of 
EU is an initiative to analyze the epigenetic, genetic and 
transcriptomic feature in ccRCC. Initially characterized 
100 patients and for other two phases 400 and 2300 
patients have been characterized19. Biomarker pipeline, a 
part of National Institute for Health and Research has 
selected 600 participants from 10 UK centers and 
sampling of fluid and tissue sample have been analyzed 
as per standard operating procedure. The main focus of 
this initiative is to evaluate the existing data and 
longitudinal and prognosis monitoring of protein 
biomarkers for future and existing assays20. In target 
therapy for renal carcinoma, genetic biomarker is used for 
the response and toxicity of the drug treatment. It is a 
European collaboration, which consists of 12 members of 
8 different countries. This initiation is based on the 
methylation, tumor gene compression and germ line 
genome21. Scottish collaboration on translational research 
(SCOTR), a Scotland base initiative has objective to 
banking of clinical samples which are obtained from the 
newly diagnosed patients22. 
 
PERSONALISED MEDICINE FOR RHEUMATOID 
ARTHRITIS 
Table 1: Marketed personalized medicine 
Trade 
name of 
drug 
Class of 
drug 
Generic name 
of drug 
Target site 
Tarceva Tyrosine 
kinase 
inhibitor 
  
  
Erlotinib Epidermal 
growth 
factor 
receptor 
 
 
 
Iressa Gefitinib 
Tagrisso Osimertinib 
Portrazza Monoclonal 
antibody 
 
 
 
Necitumumab 
Avastin Bevasizumab Vascular 
endothelial 
growth 
factor 
receptor 
  
Cyramza Ramucirumab 
keytruda Pembrolizumab Progressive 
disease 
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Table 2: Status of approved personalized drugs 
Drug name   Disease Approval 
year 
Crizonitinib Non-small cell lung 
cancer   
2013 
Erlotinib Non-small cell lung 
cancer 
2013 
Lynparza Ovarian cancer 2014 
Vimizim Mucopolysaccharidosis 2014 
Cyrazma Non-small cell lung 
cancer 
2014 
Zykadia Non-small cell lung 
cancer 
2014 
Beleodaq T- cell lymphoma 2014 
Cerdelga Gaucher disease type I 2014 
Harvoni Hepatitis C 2014 
Viekera Hepatitis C 2014 
Blincyto Acute lymphoblastic 
lymphoma 
2014 
Nucala Asthma 2015 
Cotellic Melanoma 2015 
Aristada Schizophrenia 2015 
Lonsurf Colorectal cancer 2015 
Repatha Hypercholesterolemia 2015 
Daklinza Hepatitis C 2015 
Rexulti Schizophrenia 2015 
Orkambi Cystic fibrosis 2015 
Ibrance Breast cancer 2015 
Alecensa Non-small cell lung 
cancer 
2015 
Tagrissco Non-small cell lung 
cancer 
2015 
 
Koczan et, al, The main aim of his study was to identify 
the biomarkers which will predict the outcomes of 
therapy in rheumatoid arthritis patient who get treated by 
TNF-α blocker i.e., etanercept. They selected 19 RA 
(Rheumatoid arthritis) patients and out of those, 7 
patients are non-responders and 12 patients are 
responders and changes in pre existing genes were 
monitored. The Affymetrix microarray generated a result, 
which was compared with post treatment analyzed data. 
After 72 hours of treatment, gene expression get changed 
and shows good (DAS) disease activity score i.e., 28 
>1.2. Some patient develops Interferon (IFN), which 
shows worse response to the treatment. Therefore, it is 
concluded that early prediction of RA response is 
possible when TNF-α blocker is administered based on 
their gene expression and better medication can be given 
according to their gene setup23. 
Lequerre et al, studied effect of combination of drug 
methotrexate and infliximab, response was observed after 
three months. They have selected 13 patients and gene 
profiling was done, by using mononuclear cells of 
peripheral blood. Out of those selected patients, 7 patients 
are non responder and 6 patients are responder to the 
treatment. There is a hybridization of baseline RNAs and 
transcription of mRNA. Difference in transcription level 
was compared with response and down regulation was 
observed in non responders. There are 279 genes which 
are expressed differently in case of respondents and non-
respondents24. 
 
PERSONALISED MEDICINE AND ITS 
CHALLENGES 
There are various challenges in the field of personalized 
medicines25. Some are as follows:  
Insufficient Understanding of Internal Biology of Disease   
This field is not known to all, people are not much aware 
about the concept of personalized medicine. People 
thought that Conventional medicines are sufficient for the 
treatment; another reason is insufficient knowledge about 
the genetic makeup of person and the biomarkers 
responsible for the disease.  
Limited Infrastructure 
It is main aspect that should be consider during the 
preparation of personalized medicine, the requirement of 
accessories or computerized during the gene detection or 
manipulation need more time as well as money also. 
Because of this reason also there is lack of information 
about the gene sequencing or setup of gene. For 
establishing an infrastructure of any work fund is a most 
important requirement.      
Classification of Disease 
It acknowledges that the classification system is too 
outdated and diseases mostly all the diseases comes under 
same class and based on their sign and symptoms they are 
classified. Accommodation of emerging information of 
any disease is not easy in this system therefore, subtype 
of any disease with different molecular factors is 
considered as same disease. This outdated classification 
of disease systems became the barrier for the entry of 
personalized medicine. National Academy of science 
called for a new creation called new taxonomy of all 
disease which will enhance and update the understanding 
of pathogenesis of disease and also improve the human 
health. This will also give information about the intrinsic 
biology as well as the sign and symptoms of any disease.                                                      
Accessibility of Personalized Medicine to the Patients 
It is a newer approach towards the diagnosis and 
treatment of disease and most of the people get benefit 
when they get diagnosed based on their genetic makeup 
and also they get treated but still most of the population is 
unaware about this. Because of this problem all people 
are not get diagnosed or treated so, the initiative should 
be reach to all people and increase the awareness about 
the precision medicine.                        
Implementation of Newer Diagnostics 
Clinically it is difficult for the people as well as 
physicians to apply new technique when older therapies 
are already present. It is difficult for them to interpret, 
identify and order and the overloading of information is 
also a problem, it makes the adoption difficult during new 
testing without any decision25. 
 
FDA APPROVAL OF PERSONALISED MEDICINE  
After the initiation of personalized medicine there is a 
transformation of one to all to one for individual, which 
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refers to targeting of disease by utilizing the molecular 
information, which accelerates the United States Food 
and Drug Administration (US FDA) frequently approves 
the precision medicine (Table 2). Center for drug and 
research (CDER) has approved 45 drugs out of those 13 
new novel drugs approved as personalized medicine i.e., 
more than 25% in 2015 and the classification is done by 
personalized medicine coalition (PMC). In 2014, FDA 
approved 9 medicines out of 41 as personalized medicine 
i.e., 20%. According to PMC personalized medicine are 
those products whose label contains particular biomarker 
for an individual that will help in decision-making or 
procedure for the use by individual patient26, 27. 
 
 
CONCLUSION AND FUTURE PERSPECTIVES  
Precision medicine is getting attention for its potential 
and uniqueness with its upcoming new opportunities. The 
personalized medicine is based on the discovery of 
individual genes, which cause disease. 
Pharmacogenomics is a promising field but it’s a best 
method to create new targeted therapy for any disease. 
Because of this approach we will get accuracy in the 
treatment and also the chances of side effects will also be 
reduced. This could be a better way to reduce the cost and 
time required to develop new medicine. Now, people 
believing on system which will ultimately increases the 
popularity. This initiative is not reach to all parts but 
slowly this will be helpful for developing countries also. 
This sophisticated approach could be a hope for the 
development of robustive novel biologics or bio-markers 
for disease management. The FDA has already approved 
so many medicines and in future also it will approve 
based on their novelty. This therapy is a combination of 
clinical and family history which offers the exciting and 
novel tool for drug development. As it is a challenging 
field, this could be tough to overcome all the problems 
because of its expensiveness, insufficient information, 
less awareness to the people etc. The development of 
therapies could be a tough job for all because it need 
more time to developed and need sophisticated 
commercial assay technique but at other side it might be 
beneficial for developing counties. So, the personalized 
medicine can be a better approach for early detection and 
cure of disease but for this people or future physician 
should be response and active towards the work so they 
can easily face the challenges and make this approach 
feasible to all. 
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